Backed by $52 million in Series A financing led by 8VC and named after a feat of engineering in ancient Rome, Appia Bio jumped into the cell therapy fray this morning with a promising scalable technology platform. Read more You might also be interested in News October 26, 2026“We’re In. We’ve Got You.” Freeflow’s Journey with Iambic Therapeutics News October 9, 2026Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom News June 3, 2026Freeflow Expands Into the UCSF Ecosystem
